Highlights Scholar Rock Holding Corporation

Equities

SRRK

US80706P1030

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
9.51 ^USD	+0.85%		+1.28%	-49.41%

Jun. 04	Transcript : Scholar Rock Holding Corporation - Special Call
Jun. 03	Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scholar Rock Reports 'Encouraging' Phase 1 Trial Results in Advanced Solid Tumors	Jun. 03	MT
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology Annual Meeting	May. 28	CI
Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity	May. 22	MT
Scholar Rock Holding Corporation Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity	May. 22	CI
Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss	May. 07	MT
Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management	Feb. 06	CI
Scholar Rock Says FDA Clears Application for Trial of Obesity Treatment Apitegromab	Jan. 23	DJ
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity	Jan. 23	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability	Nov. 03	CI
Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting	23-10-19	CI
Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders	23-10-11	CI
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial	23-09-19	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab	23-06-30	CI
Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Scholar Rock Holding Corporation

Equities

SRRK

US80706P1030

Highlights

Filters